Posted by Michael Wonder on 02 May 2022
Vaxxinity receives FDA fast track designation for UB-311 for treatment of Alzheimer’s disease
2 May 2022 - Vaxxinity today announced that UB-311, an anti-amyloid beta immunotherapeutic vaccine, has been granted fast track designation by the U.S. FDA for the treatment of Alzheimer’s disease.
UB-311 is an immunotherapeutic vaccine candidate targeting toxic forms of aggregated amyloid beta in the brain to treat Alzheimer’s disease.
